Pragmatic issues in biomarker evaluation for targeted therapies in cancer. - Wikidata - wikimedia - TriplyDB

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

http://www.wikidata.org/entity/Q38271031

about

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System Unveiling changes in the landscape of patient populations in cancer early drug development Current advances in biomarkers for targeted therapy in triple-negative breast cancer Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B Statistical approaches for evaluating body composition markers in clinical cancer research.Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas.Using lymph node swelling as a potential biomarker for successful vaccination.Unlocking Cancer Glycomes from Histopathological Formalin-fixed and Paraffin-embedded (FFPE) Tissue Microdissections.Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data.Clinical potential of gene mutations in lung cancer.CombiROC: an interactive web tool for selecting accurate marker combinations of omics data.CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff?An appraisal of drug development timelines in the Era of precision oncology.Search for Master Regulators in Walking Cancer Pathways.Stem Cell Extracellular Vesicles: Extended Messages of Regeneration.Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes.Fe3O4 nanoparticles on graphene oxide sheets for isolation and ultrasensitive amperometric detection of cancer biomarker proteins.Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours.The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma.Drug-perturbation-based stratification of blood cancer.Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.Unearthing new genomic markers of drug response by improved measurement of discriminative power.

P2860

Q26771952-DAA8AAE1-78A7-4A89-B0AA-26FD6CEF75E9 Q26796208-BF55097B-7E70-4B62-9762-AD0C5EC97D18 Q28073826-354FC12C-7362-44B2-9810-140D867F379B Q28074202-6E179DD1-FCBA-459F-8D3E-2590A0FB30CF Q28083256-057D80E3-4489-4188-B475-87107FFAC38B Q28551145-415BB20E-19B1-462C-88AA-C52F1578924A Q30235361-C141B128-5B02-43A9-9B15-E11F9C99A966 Q30398758-0AA46068-94AB-48AE-885A-BAA24D41CC1C Q31132980-76E1A1CD-31F0-4671-B313-0A436310EE80 Q33607435-86D59B1C-854C-4E8E-ABB5-C1834D8D4FD8 Q33920189-3E89ECEC-4E1C-4B39-8605-9DA66EBF8B57 Q35752063-C3AF15F1-2FBA-4119-95FE-5DD731A9197E Q36032562-7F824C62-006A-4C4B-B5C3-0EAECB0509DC Q36260470-6655BABD-0413-4E99-B91E-610EAD431535 Q36279137-03D64ABF-B39F-4761-8A2C-3E2FF429F858 Q36309864-E98948C9-A652-4F7F-AE55-7FDD8DD01D30 Q36316009-00E67CF7-CA2F-41DA-8FEB-DA5B8EE785E2 Q36327857-D1EC6EAE-7368-489C-816D-B16C5FD9D40B Q36685525-A58BA0B2-2AB9-47FC-8A7E-F5837C240385 Q36731185-1FDE3A94-F82F-4E9C-BC68-1D063FF228E8 Q36847816-CBDE253F-674E-41C1-9AF6-BC70D5D2FE20 Q37256316-5C6B4540-28AC-4EEE-A180-50C0581B1FDB Q37619700-F44467AE-8BF5-499F-B166-6323ADA47407 Q38604272-2C468560-CE3B-48C8-AD49-60C55B90958B Q38798555-46BA0565-DB33-4204-8C92-4DE7365ED6A1 Q38818107-35DDD625-42A6-46CC-96BA-CB952A1DBDC6 Q38868832-3F04C439-179A-4FA8-9496-2FBA7389EE8E Q41238074-45EFB758-1411-47E7-B442-4A618CD5C41C Q41603225-9B9CA07D-6BB4-42DF-8D7B-E9FDF6AB59E2 Q42363185-D2B9BAF2-61E1-4FB8-8744-17763678838B Q42378446-7E530195-35B9-441F-A397-7475C9F84188 Q44109828-B71AB818-07E2-443C-8E0B-A21F00AE55F8 Q45943066-76262493-DB19-4242-B213-EC64BB9DCA16 Q47110861-3121AFD5-24CF-4B0D-800D-9FC9B586F41D Q47284899-4ADA3576-D961-49AB-B3C0-887110E72379 Q47331796-BA430416-6C02-40A5-85E9-21D73551DB5B Q47374639-874F6F61-14AA-4ADB-846B-C72C3291FD88 Q47392574-32AACE00-20EF-4AC7-9D9E-59F25FECEF1F Q48093681-C1D791D3-55D8-450D-8E48-C021A9CA66CA Q49530462-C0EA8A8F-108E-4EE4-9A49-330793D9A8FE

P2860

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

http://www.wikidata.org/entity/Q38271031

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

@en

type

label

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

@en

prefLabel

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

@en

P1433

Q38271031-0EB7BACF-970B-4CBA-9F41-9BA854DD2EF0

P1476

Q38271031-969E2032-BDBE-4855-A131-B267290C6C33

P2093

Q38271031-3A72EB44-F4A4-42C5-A873-BE35841F4D06

Q38271031-76B7F089-BE96-4F2E-8F87-814D815E25E9

Q38271031-9DCC1A02-760C-41C2-BB8B-78C95314C962

Q38271031-C8A79CD0-FA83-4C41-B35B-FA5A4DC40FA6

Q38271031-EB4962C8-30AB-4584-B7FE-12E3E04C2A41

P2860

Q38271031-02D3E757-B102-470A-8096-AEA69BFB5307

Q38271031-07559872-10AF-4F76-B6B0-BAEECF735F5D

Q38271031-09A586C2-7592-44E2-BAA7-E7829A405FB4

Q38271031-0AE12178-FB8A-43DC-B163-71A94DD70521

Q38271031-0B248D66-2A16-4A64-8AFC-0A4CAD066E23

Q38271031-0F0CFAA4-2E82-43D4-A044-C2F59235EC08

Q38271031-10133A7D-8770-4203-A701-08D37BB44A0F

Q38271031-10AFECF7-E976-44EB-810E-63F368A4E0DA

Q38271031-114EA4D0-1E0A-4F74-9D50-60906DCD5E71

Q38271031-13E641CA-D824-4EA8-BAD7-02DAAC1B879E

P304

Q38271031-205099D0-0677-4C6B-B4DE-1FDA5176A158

P31

Q38271031-73ABB5E2-82D9-4BCA-8B76-305423BBC67F

P356

Q38271031-B8C2E1BA-DF01-42A4-8658-1163CC5BBED1

P407

Q38271031-02AAF927-19CA-43E1-8D60-939A43B743C8

P433

Q38271031-F4D620D0-0F26-4869-8C2B-4B170E24D340

P478

Q38271031-BF6C8F0B-8661-4BB0-90BE-957D0ABF4F22

P50

Q38271031-9964CDFE-ECAF-4401-978A-8CD5C3E14517

Q38271031-9AC35BA8-6BDF-442B-84CF-206A839D0C09

P577

Q38271031-2D4411F7-F6F6-4289-B1C3-23CC4FA0252F

P5875

Q38271031-13EDD252-9C0A-47B0-B664-C7EA0166A45B

P698

Q38271031-5EA0B872-1470-4D52-9CBB-AEC87D8819FB

P921

Q38271031-A55AE535-BF3D-402A-8A66-723FDE9D9566

P356

NRCLINONC.2014.202

P1433

Nature Reviews Clinical Oncology

P1476

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

@en

P2093

Armand de Gramont

http://www.w3.org/2001/XMLSchema#string

Jordi Rodón

http://www.w3.org/2001/XMLSchema#string

Lee M Ellis

http://www.w3.org/2001/XMLSchema#string

Sarah Watson

http://www.w3.org/2001/XMLSchema#string

Stanley R Hamilton

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

P304

197-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2014.202

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

Aimery de Gramont

P577

2014-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268873456

http://www.w3.org/2001/XMLSchema#string

P698

25421275

http://www.w3.org/2001/XMLSchema#string

P921